Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

This study found that both androgenetic alopecia and alopecia areata showed significantly increased DKK-1 expression, potentially implicating it in the pathogenesis and as a treatment target for these conditions.

This abstract does not report results but indicates that the supplementary material includes comprehensive methodology, additional results, statistical analyses, discussion, and limitations of the Alopecia Areata Relapse Study Group's findings as presented in the main manuscript.

In this study, researchers found that patients with severe alopecia areata show varied regrowth timelines with baricitinib, and those with the most severe cases may still experience delayed but eventual improvement.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

This review discusses the role of keratinocytes in hidradenitis suppurativa, highlighting their genetic and metabolic influences on disease progression without presenting new clinical results.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This study observed that patients with autism spectrum disorder have a higher risk of developing alopecia areata compared to those without ASD, suggesting a possible link between the two conditions.

This study found that aPKCλ, but not aPKCζ, plays a critical role in maintaining hair follicle stem cell populations and promoting wound healing in the epidermis.

This chapter discusses a case of sebaceous adenitis in a Japanese Akita, providing educational material for students and practitioners but reports no new research findings.

This study provided the first X-ray crystal structure of the mammalian steroid hormone reductase AKR1D1 and identified a disease-related mutant, P133R, which may impact bile acid metabolism and cause clinical symptoms.

This study suggests that EDA-A2 induces apoptosis in hair follicles by increasing DKK-1 expression, implicating EDA2R signaling as a potential therapeutic target for androgenetic alopecia.

In a mouse model study, researchers found that mutations in Aire reduced alopecia areata frequency, while Notch4 mutations did not lead to the disease, likely due to proximity with a resistance gene.

This report describes a case of alopecia areata incognita in a 6-year-old child, marked by sudden diffuse hair loss without bald patches, typically observed in adults.

In this study, Dodatek A operationalizes the Functional Androgen Axis framework by defining three system-level indices and an efficiency metric to describe androgen function, incorporating key methodological improvements and acknowledging significant limitations for future empirical validation.

This study found that while infectious events may occur in alopecia areata patients treated with JAK inhibitors, these infections are usually manageable and rarely lead to permanent treatment discontinuation.

Daylight photodynamic therapy is effective and well-tolerated for treating actinic keratoses with minimal side effects.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.

Acankoreoside J from Acanthopanax koreanum may help promote hair growth.

In this case report, a patient with diffuse alopecia areata experienced complete hair regrowth after treatment with oral abrocitinib, with no adverse effects observed.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

This study presented two brothers with hereditary acrodermatitis enteropathica who had normal zinc serum levels and experienced skin and hair lesions, but no dental disorders.

This study found that ethanol extracts of A. koreanum improved serum cholesterol levels and protein recovery in rats with dry skin compared to water extracts.

AUC and APL are distinct conditions needing careful clinical assessment.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

This study suggests that the rs2075876 variant in the AIRE gene may significantly increase susceptibility to alopecia areata in the examined male population.

Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.